Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

2023655 citationsJournal Articlegreen Open Access

Authors

Jesús F. San Miguel · Centro de Investigación del Cáncer

Binod Dhakal · Medical College of Wisconsin

Kwee Yong · Cancer Institute (WIA)

Andrew Spencer · Australian Regenerative Medicine Institute

Sébastien Anguille · Antwerp University Hospital

María‐Victoria Mateos · Instituto de Investigación Biomédica de Salamanca

Carlos Fernández de Larrea

Abstract

A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 4, pp. 335-347

DOI: 10.1056/nejmoa2303379

Field-Weighted Citation Impact: 188.92